4.1 Article

Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020)

Journal

GASTROENTEROLOGIA Y HEPATOLOGIA
Volume 43, Issue 9, Pages 559-587

Publisher

ELSEVIER ESPANA SLU
DOI: 10.1016/j.gastrohep.2020.03.011

Keywords

Hepatitis B; AEEH document; Entecavir; Tenofovir; Tenofovir atafenamide; Interferon; HBsAg; HBV-DNA; Hepatoceltutar carcinoma

Ask authors/readers for more resources

Hepatitis B virus (HBV) infection remains a global public health problem. HBV vaccination is the most effective tool to reduce the incidence of HBV disease. Despite there has not been new clinical developments for the treatment of chronic hepatitis B in the last few years, changing epidemiology and current insights on natural history, diagnostic tools and therapy indications make necessary an update of the former version of the consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B infection published in 2012. The current document updates the management of chronic hepatitis B. The treatment of choice is the long-term administration of a nucteos(t)ide analogue with high barrier to resistance (entecavir, tenofovir or tenofovir alafenamide). Pegylated interferon may be an option in patients with non-advanced liver disease, but its applicability is limited due to the low efficacy and poor tolerability. All patients must be monitored for the risk of progression to advanced liver disease and development of hepatocellular carcinoma. (C) 2020 Elsevier Espana, S.L.U. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available